What Happened?
Boston, MA-based Entrada-Therapeutics Appointed Dipal Doshi as President and Chief Executive Officer
About the Company
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company`s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system.
About the Person
Dipal Doshi is President and Chief Executive Officer at Entrada Therapeutics. Previously, Dipal held various senior HR leadership roles in the industry.
Info Source
News
Short Profile